Iodine Symporter Targeting with <sup>124</sup>I/<sup>131</sup>I Theranostics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28864610.
- Also identified by DOI 10.2967/jnumed.116.186866.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuclear medicine for optimizing and individualizing treatments for many cancer entities. Theranostics has been used in clinical routines in nuclear medicine for more than 60 y-as <sup>131</sup>I for diagnostic and therapeutic purposes in thyroid diseases. In this minireview, we provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium-iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a brief summary of theranostics for neuroendocrine neoplasms and metastatic castration-refractory prostate cancer. In particular, we discuss the role of <sup>124</sup>I-based dosimetry in targeting of the sodium-iodine symporter and describe the clinical application of <sup>124</sup>I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation treatment with the mitogen-activated extracellular signal-related kinase kinase inhibitor trametinib.
Medical subject headings
- Iodine
- Iodine Radioisotopes
- Membrane Transport Proteins
- Molecular Targeted Therapy
- Sodium